EU4

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, A-T, DSP, Disease, SPA, Half-life, Hematology, Patient, NDA, EU4, Acquisition, Standard of care, Pivotal, Cancer, Quality of life, Biology, AIDE, Investment, Clinical trial, Therapy, NEAT, FDA, Pharmaceutical industry

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
  • Pivotal Phase 3 NEAT clinical trial will be conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food & Drug Administration (FDA).
  • Expect to report Phase 3 NEAT topline results in the second half of 2025 with a potential NDA submission in 2026, assuming positive study results.
  • Quince estimates there are an aggregate of approximately 10,000 patients with A-T in the U.S., U.K., and EU4 countries.

TRS01 for Autoimmune Uveitis in Seven Major Markets: Size, Forecasts, and Emerging Insights, 2019-2023 and 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 7, 2024
Health, Pharmaceutical, Toll-like receptor 4, Uveitis, SWOT, EU4, TRS, Autoimmunity, TLR4, Research, Immune system, Pharmaceutical industry

This report provides comprehensive insights about TRS01 for autoimmune uveitis in the seven major markets.

Key Points: 
  • This report provides comprehensive insights about TRS01 for autoimmune uveitis in the seven major markets.
  • Further, it also consists of future market assessments inclusive of the TRS01 market forecast analysis for autoimmune uveitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in autoimmune uveitis.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TRS01 in autoimmune uveitis.
  • The report also features the SWOT analysis with analyst views for TRS01 in autoimmune uveitis.

Monoamine Oxidase Type-B (MAO-B) Inhibitors for 7 MM: Market Size, Target Population, Competitive Landscape & Forecasts, 2034 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Health, Pharmaceutical, Therapy, Key, Inflation, Competitive landscape, Monoamine oxidase, Physician, News, Opinion, SWOT, EU4, Inhibitor, Safety, HTA, Patient, Disease, Drug, Mutation, Pharmaceutical industry

The "Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Monoamine Oxidase Type-B (MAO-B) Inhibitors market report provides insights around existing treatment practices in patients with Monoamine Oxidase Type-B (MAO-B) Inhibitors, approved (if any) and emerging Monoamine Oxidase Type-B (MAO-B) Inhibitors, market share of individual therapies, patient pool eligible for treatment with Monoamine Oxidase Type-B (MAO-B) Inhibitors, along with current and forecasted 7MM Monoamine Oxidase Type-B (MAO-B) Inhibitors market size from 2020-2034 by therapies and by indication.
  • This section will include details on changing Monoamine Oxidase Type-B (MAO-B) Inhibitors market dynamics post initiation of clinical development activities of the inhibitor.
  • The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Monoamine Oxidase Type-B (MAO-B) Inhibitors.

FARXIGA Market Insights and Advanced Forecast Report Reveal Critical Developments in Myocardial Infarction Treatment by 2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024
Health, Pharmaceutical, Research, Growth, SWOT, EU4, Myocardial infarction, Patient, Clinical trial, SGLT2, Heart, Closer, Pharmaceutical industry

The "FARXIGA Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "FARXIGA Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
  • The comprehensive new report detailing FARXIGA's impact and projected growth in the myocardial infarction treatment landscape over the next decade is now available, offering crucial insights into the medication's effectiveness, development, and market projection through 2032.
  • The report deep dives into FARXIGA's (dapagliflozin) market potential, with its mechanism of action against myocardial infarction extensively analyzed.
  • FARXIGA stands in the spotlight, with potential new applications poised to further establish its position in the treatment regimen for myocardial infarction.

Anti-Integrin Agents Market Research Report 2024: In-Depth Analysis on Size, Target Population, Competitive Landscape and Forecast to 2034 - Focus on 7 Major Markets - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024
Health, Pharmaceutical, Therapy, Competitive landscape, News, SWOT, EU4, Internet, Accessibility, Patient, Research report, KOL, Pharmaceutical industry

The "Anti-integrin Agents Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-integrin Agents Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • This detailed publication offers critical insights into the current and future landscape of Anti-integrin Agents, covering the gamut from existing treatments to emerging therapies.
  • The report delves into the competitive landscape of individual therapies, the patient pool eligible for Anti-integrin therapy, and also examines the market share of these treatments.
  • Strategic Market Forecast: Forecasted market trends propelling the Anti-integrin Agents market will equip stakeholders with key knowledge, aiding in strategic decision-making.

Complement Inhibitors (C3/C5) Market Poised for Significant Growth by 2034 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Pharmaceutical, Health, Competitive landscape, SWOT, EU4, Internet, Element, Disorder, Research, Pharmaceutical industry

The "Complement Inhibitors (C3/C5) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Complement Inhibitors (C3/C5) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • Expanding at a Robust Pace, the Complement Inhibitors (C3/C5) Market Sees Advancements and Detailed Forecast
    The latest market research publication offers a comprehensive analysis of the Complement Inhibitors (C3/C5) market and its anticipated growth trajectory through 2034.
  • Through granular insights into the Complement Inhibitors (C3/C5) market, the report elucidates the potential for these therapies in improving patient care for those suffering from disorders linked to the complement system.
  • These insights are invaluable for stakeholders strategizing to navigate the complex and evolving Complement Inhibitors (C3/C5) market.

JARDIANCE Market Size, Forecast, and Emerging Insights, 2019-2023 and 2024-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2024
Health, Pharmaceutical, Heart, AMI, EMPOWER, SWOT, EU4, Empagliflozin, Risk, Myocardial infarction, Safety, Acute kidney injury, Patient, SGLT2, Urine, Kidney, Glucose, Kidney disease, Mortality, Research, Pharmaceutical industry

Further, it also consists of future market assessments inclusive of the JARDIANCE market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Key Points: 
  • Further, it also consists of future market assessments inclusive of the JARDIANCE market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.
  • JARDIANCE (Empagliflozin) is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for glucose re-absorption in the kidney.
  • The report also highlights the JARDIANCE research and development activities in myocardial infarction across the United States, Europe and Japan.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JARDIANCE in myocardial infarction.

Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 with Focus on 7 Major Markets - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024
Pharmaceutical, Health, Clinical Trials, Therapy, Key, Inflation, Competitive landscape, Physician, News, Opinion, SWOT, EU4, AIS, Safety, HTA, Patient, Clinical trial, Disease, Enzyme inhibitor, Drug, Mutation, Epidemiology, Pharmaceutical industry

The "Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Aromatase Inhibitors (AIs) market report provides insights around existing treatment practices in patients with Aromatase Inhibitors (AIs), approved (if any) and emerging Aromatase Inhibitors (AIs), market share of individual therapies, patient pool eligible for treatment with Aromatase Inhibitors (AIs), along with current and forecasted 7MM Aromatase Inhibitors (AIs) market size from 2020-2034 by therapies and by indication.
  • Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications.
  • This section will include details on changing Aromatase Inhibitors (AIs) market dynamics post initiation of clinical development activities of the inhibitor.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, General Health, Pharmaceutical, Health, Therapy, Inflation, Competitive landscape, PCSK9, Proprotein convertase, Physician, News, SWOT, EU4, Safety, HTA, Patient, Disease, Drug, Mutation, Epidemiology, Pharmaceutical industry

The "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors market report provides insights around existing treatment practices in patients with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, approved (if any) and emerging Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, market share of individual therapies, patient pool eligible for treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, along with current and forecasted 7MM Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors market size from 2020-2034 by therapies and by indication.
  • The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors marketed drug section will provide detailed drug profiles of already approved therapies.
  • The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.

MEDI8897 (Nirsevimab): An Investigational Long-Acting Antibody that Protects all Infants through their First RSV Season with a Single Dose - Market Size, Forecasts, and Market Insight 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Health, Pharmaceutical, RSV, AstraZeneca, Immunization, FDA, SWOT, EU4, Nirsevimab, Sanofi, Infant, Ventricular septal defect, Disease, Research, Immune system, Pharmaceutical industry

The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.

Key Points: 
  • The report provides comprehensive insights about MEDI8897 for Respiratory syncytial virus (RSV) in the seven major markets.
  • MEDI8897 (Nirsevimab) is an investigational long-acting antibody that protects all infants through their first RSV season with a single dose.
  • Nirsevimab is an immunization that provides direct prophylactic RSV protection to all infants via an antibody to help prevent LRTI caused by RSV.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MEDI8897 in RSV.